Concurrent cisplatin chemotherapy

Phase 2Small molecule

Concurrent cisplatin chemotherapy is one of 4 small molecule programs targeting Chemoradiation. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ChemoradiationRecruiting

ChemoradiationPhase 2

Recruiting

Competition

Competitive Landscape

4 competitors in Chemoradiation

#DrugCompanyPhaseTrials

Tuoyi

SSun Yat-sen University

Phase 2

1 2

S1,

CChinese Academy of Medical Sciences

Phase 2

1 3

Iparomlimab

TTianjin Medical University Cancer Institute and Hospital

Phase 2

1 4

Concurrent cisplatin chemotherapy

CChongqing University Cancer Hospital

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Chemoradiation

NCT05213884

Clinical

Trials by Indication[1]

Chemoradiation1 trial

The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC

Recruiting·—·Phase 2·NCT05213884·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Concurrent cisplatin chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Concurrent cisplatin chemotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Concurrent cisplatin chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Chongqing University Cancer Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CChongqing University Cancer Hospital

Concurrent cisplatin chemotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Chemoradiation1 trial

References

Drug Info

Quick Facts

Related News